DMD
Clinical Outcomes Validation in Non Ambulatory and Young Boys/Men With Duchenne Muscular Dystrophy (DMD)
Sponsor study identifier
observational
50
1 country
1
Study Start
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2013
Actual (reported)Study Completion
November 2013
Actual (reported)Many therapeutic trials in DMD exclude non-ambulatory boys and men. Rate of progression in these non-ambulatory patients has been studied but consensus has not been reached for what measures are most reliable and reproducible. Furthermore, any treatment trial would be expected to demonstrate improved function and improvement in quality of life. Therefore, function, strength, and quality of life must be understood and standardized. While the goal of this proposal is to standardize clinical outcomes for therapeutic trials, careful understanding of the progression of DMD in non ambulatory boys may also lead to better medical treatment.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2013
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
April 1, 2010
Actual (reported)April 5, 2010
Actual (reported)November 2013
Actual (reported)November 2013
Actual (reported)Dystrophin gene mutations that predispose to early onset cardiomyopathy
3 years
Non ambulatory boys and men with Duchenne muscular dystrophy
Washington University
St Louis, Missouri, 63110, United States
Anne Connolly, M.D.
Washington University School of Medicine
50 participants (actual enrollment reported by the registry).
First Submitted
April 1, 2010
First Posted
April 5, 2010
Study Start
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)
Contact the study team to confirm eligibility.
Primary Completion
November 2013
Actual (reported)Study Completion
November 2013
Actual (reported)Last Updated
January 18, 2017
Record last verified: 2017-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: